Evaluation of two commercial methods for the susceptibility testing of Candida species: Vitek 2® and Sensititre YeastOne®
Revista Iberoamericana de Micología · 2018-04 · 35 (2) · 83-87
DOI: 10.1016/j.riam.2017.11.001 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Revista Iberoamericana de Micología, 2018-04. Verfasst von Ricardo Andreotti Siqueira und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Israelita Albert Einstein, Clinical Laboratory, São Paulo, Brazil. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: An increased incidence of fungal infections caused by Candida species, especially Candida glabrata and Candida krusei, which are less susceptible to azoles, has been observed. Standardized susceptibility testing is essential for clinical management and for monitoring the epidemiology of resistance. AIMS: We evaluated the performance of two different susceptibility testing commercial methods, Vitek 2® and Sensititre YeastOne®, and compared them with the standard broth microdilution method (CLSI). METHODS: A total of 80 isolates of several Candida species (Candida albicans, Candida parapsilosis complex, Candida tropicalis, C. glabrata and C. krusei) were selected for this study. RESULTS: We analyzed the categorical agreement (CA) between the methods, stratifying the disagreements. The average CA between the methods was 96.3% for Vitek 2® and 84% for Sensititre YeastOne®. No very major errors were observed. Major errors and minor errors were found for all the isolates tested. With the azoles, both Vitek 2® and Sensititre YeastOne® had good and similar performance levels, except for C. tropicalis and C. krusei (Sensititre YeastOne® showed low CA, 56.2%). With the echinocandins, both methods showed good performance for C. albicans, C. parapsilosis and C. tropicalis. However, we observed important discrepancies for C. krusei with caspofungin: Vitek 2® had 100% CA while Sensititre YeastOne® had only 25%. With amphotericin B, both Vitek 2® and Sensititre YeastOne® had good performance with high CA. CONCLUSIONS: Despite the limited isolates tested, we concluded that both methods have good performance and are reliable for antifungal susceptibility testing. However, caspofungin activity against C. krusei and C. glabrata should be interpreted carefully when using Sensititre YeastOne® because we observed a low CA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital Israelita Albert Einstein, Clinical Laboratory, São Paulo, Brazil.
- Hospital Israelita Albert Einstein, Clinical Laboratory, São Paulo, Brazil. Electronic address: andre.doi@einstein.br.
Zitieren
APA
Siqueira, R. A., Doi, A. M., de Petrus Crossara, P. P., Koga, P. C. M., Marques, A. G., Nunes, F. G., Pasternak, J., & Martino, M. D. V. (2018). Evaluation of two commercial methods for the susceptibility testing of Candida species: Vitek 2® and Sensititre YeastOne®. Revista Iberoamericana de Micología, 35(2), 83-87. https://doi.org/10.1016/j.riam.2017.11.001
Vancouver
Siqueira RA, Doi AM, de Petrus Crossara PP, Koga PCM, Marques AG, Nunes FG, et al. Evaluation of two commercial methods for the susceptibility testing of Candida species: Vitek 2® and Sensititre YeastOne®. Revista Iberoamericana de Micología. 2018;35(2):83-87. doi:10.1016/j.riam.2017.11.001
BibTeX
@article{Siqueira2018,
author = {Siqueira, Ricardo Andreotti and Doi, Andre Mario and de Petrus Crossara, Paulo Petrus and Koga, Paula Celia Mariko and Marques, Alexandre Gimenes and Nunes, Fabiane Gomes and Pasternak, Jacyr and Martino, Marines Dalla Valle},
title = {Evaluation of two commercial methods for the susceptibility testing of Candida species: Vitek 2® and Sensititre YeastOne®},
journal = {Revista Iberoamericana de Micología},
year = {2018},
volume = {35},
number = {2},
pages = {83--87},
doi = {10.1016/j.riam.2017.11.001}
}
EUVIMED